Develops and markets advanced genome analysis tools and services, focusing on structural variation detection in genomic data.
Bionano Genomics, Inc., headquartered in San Diego, California, is a pioneering provider of genome analysis software solutions. Established in 2003, the company is at the forefront of optical genome mapping technology with its flagship product, Saphyr. Saphyr is a comprehensive sample-to-result solution designed for structural variation analysis, enabling precise insights into genetic variation and function. Key components of the Saphyr system include the Saphyr instrument, a state-of-the-art single-molecule imager, and the Saphyr Chip, a consumable that houses nanochannel arrays essential for DNA linearization.
In addition to its cutting-edge hardware, Bionano Genomics offers a range of supporting products such as Bionano Prep Kits and DNA labeling kits. These kits provide essential reagents and protocols for the extraction and labeling of ultra-high molecular weight DNA, facilitating accurate genetic analysis. The company also provides Saphyr and Bionano compute servers, enhancing computational capabilities for genome data processing. Furthermore, Bionano Genomics extends its offerings with NxClinical, a comprehensive system for the analysis and interpretation of genomic variants derived from microarray and next-generation sequencing data in the fields of cytogenetics and molecular genetics.
Bionano Genomics is committed to advancing diagnostic capabilities through its testing and laboratory services. These include FirstStepDx PLUS, a chromosomal microarray designed to identify genetic causes underlying conditions such as autism spectrum disorder, developmental delay, and intellectual disability. The company also offers specialized testing services for Fragile X syndrome, exome sequencing through NextStepDx PLUS for childhood development disorders, and EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures or other related conditions. Additionally, Bionano Genomics provides pharmacogenomic (PGx) testing to identify specific genetic alleles related to drug metabolism and response, contributing to personalized medicine initiatives globally.